Emcure Pharmaceuticals Limited has announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. This agreement, effective April 1, 2026, aims to enhance patient access to critical therapies for chronic kidney disease (CKD), anemia management, and transplant care across India. Under the terms of the agreement, Emcure will distribute Roche's established brands, including CellCept® (an immunosuppressant for organ transplants), Mircera®, and Neorecormon® (therapies for anemia in CKD). This collaboration is expected to complement Emcure's existing offerings in anemia management and the nephrology segment, allowing them to expand their portfolio and reach a wider patient base. Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals, stated that the partnership is a natural extension of Emcure's commitment to improving outcomes in renal care. Rajji Mehdwan, Managing Director & CEO of Roche India & Neighbouring Markets, expressed confidence that Emcure's distribution network will help these medicines reach more patients who can benefit from them.
